FindTrial
Sign In

Dimethyl Fumarate (DMF)

DRUG6 trials

Sponsors

Biogen, Robert Lafyatis, Genesis Pharma CNS & Specialty, Hikma Pharmaceuticals LLC, Novartis Pharmaceuticals

Conditions

HealthyMultiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingPulmonary; HypertensionRRMSRelapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSkin Cancer

Phase 1

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily
CompletedNCT01915901
BiogenHealthy
Start: 2013-08-31End: 2013-12-31Updated: 2014-03-03
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
TerminatedNCT02981082
Robert LafyatisPulmonary; Hypertension, Systemic Sclerosis
Start: 2016-12-31End: 2020-02-10Updated: 2022-03-17

Unknown Phase

Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece
CompletedNCT03101735
Genesis Pharma CNS & SpecialtyRRMS
Start: 2016-09-23End: 2020-04-23Updated: 2021-07-28
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
CompletedNCT04468165
Hikma Pharmaceuticals LLCRelapsing Remitting Multiple Sclerosis
Start: 2021-02-23End: 2023-07-20Updated: 2023-09-22
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
RecruitingNCT05344469
Novartis PharmaceuticalsRelapsing Multiple Sclerosis
Start: 2022-05-10End: 2029-05-30Target: 800Updated: 2026-07-30
Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study
CompletedNCT06705608
University of British ColumbiaMultiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Skin Cancer +3
Start: 2003-01-01End: 2020-12-31Target: 4000Updated: 2024-11-26

Related Papers

The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study.
2025-12-18
Fingolimod and risk of skin cancer among individuals with multiple sclerosis: a population-based cohort study protocol
BMJ Open2025-01-01
The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study
2025-01-01
The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- the fidelity study
2025-01-01
The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study
2025-01-01
The economic impact, healthcare resource utilization, and clinical outcome over 24 months in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate in Greece- The Fidelity Study
2025-01-01
Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
2018-11-1510 citations